A Real-world Study for Patients With Multiple Pulmonary Ground-glass Nodules

Multiple Pulmonary Nodules Clinical Trial

Official title:

A Real-world Study for Patients With Multiple Pulmonary Ground-glass Nodules

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT04192201
• Other study ID #: TJ-LC-02
• Status: Not yet recruiting
• Start date: December 31, 2019
• Est. completion date: December 31, 2024

Study information

• Verified date: October 2019
• Source: Tongji Hospital
• Contact: Xiangning Fu, MD
• Phone: +8613607150390
• Email: fuxn2006[@]aliyun.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to actively monitor patients with multiple pulmonary Ground-glass Nodules (GGNs), in order to provide evidence for multiple GGNs treatment.

Description:

Multiple pulmonary GGNs are very commonly identified particularly as increasing numbers of CT scans are performed as part of routine lung cancer screening. At the same time, the ideal solution for these cases continues to be debated. This aim of this study is to learn more about the effects of multiple factors on outcome of multiple pulmonary GGNs, such as patients' clinical characteristics, CT features and different pathological types. Furthermore, the optimal timing of surgery and the effect of different surgical choices on the prognosis of patients with multiple GGNs will be investigated.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 200
• Est. completion date: December 31, 2024
• Est. primary completion date: December 31, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Age greater than 18 years

2. Have two or more GGNs on CT imaging

3. Diameter of GGNs > 5mm and = 3cm

4. GGNs must be greater than half ground glass

Exclusion Criteria:

1. patients who have a history of lung cancer

2. patients who have undergone chemotherapy, radiotherapy or targeted therapy before surgery

3. pregnant women

Related Conditions & MeSH terms

• Multiple Pulmonary Nodules

Locations

Country	Name	City	State
China	Tongji Hospital	Wuhan	Hubei

Sponsors (1)

Lead Sponsor	Collaborator
Tongji Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	5-year overall survival [Time Frame: From date of the recruitment, assessed up to 60 months]	5-year overall survival	October 31, 2024
Secondary	5-year Progression-Free-Survival [Time Frame: From date of the recruitment, assessed up to 60 months]	5-year Progression-Free-Survival	October 31, 2024
Secondary	Recurrence-free survival [Time Frame: From date of the recruitment, assessed up to 60 months]	Recurrence-free survival	October 31, 2024